Trial
NCT03954106
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jazz Pharmaceuticals
Collaborators
—
Condition
DLBCL
Intervention
Defibrotide
Why stopped
Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20 efficacy evaluable patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-09